Announcements


Date: 28 April 2017

OTHERS ASIA BIOENERGY TECHNOLOGIES BERHAD ("ABT" or "the Company") -ANNOUNCEMENT PURSUANT TO RULE 9.20 OF THE ACE MARKET LISTING REQUIREMENTS


Type Announcement
Subject OTHERS
Description ASIA BIOENERGY TECHNOLOGIES BERHAD ("ABT" or "the Company") -ANNOUNCEMENT PURSUANT TO RULE 9.20 OF THE ACE MARKET LISTING REQUIREMENTS

Pursuant to Rule 9.20 of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, Asia Bioenergy Technologies Berhad (“ABT” or “the Company”) wishes to announce that as at 27 April 2017, the aggregate value of quoted securities purchased by Asiabio Capital Sdn Bhd (“ACSB”), a wholly owned subsidiary of the Company that is principally involved in the investment in marketable securities, that has not been announced for the preceding twelve (12) months has exceeded 5% of ABT's latest audited consolidated net assets as at 31 March 2016. The details of the investment in the quoted securities are as follows:-

RM

% of ABT's latest audited consolidated net assets

a.

Aggregate purchase consideration within the preceding twelve (12) months

2,915,944.59

7.29

RM

b.

Investments in quoted securities as at 27 April 2017

- Total Cost

48,359,473.11

- Total Book Value

47,636,637.24

- Total Market Value

52,450,319.35

c.

Net gain/(loss) arising from the sale of quoted securities by ABT Group during the current financial year ended 31 March 2017
(Sales proceeds less investment cost and incidental expenses)

-

The purchase of the quoted securities as announced were made within a period between 13 April 2017 to 27 April 2017.

This announcement is dated 28 April 2017.







Back